Metformin rescues Parkinson's disease phenotypes caused by hyperactive mitochondria. Author Danielle Mor, Salman Sohrabi, Rachel Kaletsky, William Keyes, Alp Tartici, Vrinda Kalia, Gary Miller, Coleen Murphy Publication Year 2020 Type Journal Article Abstract Metabolic dysfunction occurs in many age-related neurodegenerative diseases, yet its role in disease etiology remains poorly understood. We recently discovered a potential causal link between the branched-chain amino acid transferase and the neurodegenerative movement disorder Parkinson's disease (PD). RNAi-mediated knockdown of is known to recapitulate PD-like features, including progressive motor deficits and neurodegeneration with age, yet the underlying mechanisms have remained unknown. Using transcriptomic, metabolomic, and imaging approaches, we show here that knockdown increases mitochondrial respiration and induces oxidative damage in neurons through mammalian target of rapamycin-independent mechanisms. Increased mitochondrial respiration, or "mitochondrial hyperactivity," is required for neurotoxicity. Moreover, we show that post-disease-onset administration of the type 2 diabetes medication metformin reduces mitochondrial respiration to control levels and significantly improves both motor function and neuronal viability. Taken together, our findings suggest that mitochondrial hyperactivity may be an early event in the pathogenesis of PD, and that strategies aimed at reducing mitochondrial respiration may constitute a surprising new avenue for PD treatment. Keywords Animals, Disease Models, Animal, Caenorhabditis elegans, Phenotype, Neurons, Caenorhabditis elegans Proteins, Mitochondria, Amino Acids, Branched-Chain, Parkinson Disease, Metformin Journal Proc Natl Acad Sci U S A Volume 117 Issue 42 Pages 26438-26447 Date Published 2020 Oct 20 ISSN Number 1091-6490 DOI 10.1073/pnas.2009838117 Alternate Journal Proc Natl Acad Sci U S A PMCID PMC7585014 PMID 33024014 PubMedPubMed CentralGoogle ScholarBibTeXEndNote X3 XML